|
Experts from the lifesciences domain averred that investments into digital technology would accelerate innovation and efficiency. It is here that events like Global Tech Summit 2023, to be held at Visakhapatnam from February 16–17 are positioned as an ideal platform to ascertain new technologies in drug discovery, to make medicines more affordable.
Recently, the Global Tech Summit team, led by Dr. Srinubabu Gedela, CEO, Pulsus Group, organised a roadshow and business-to-biopharma digital transformation meeting at Nagpur which was the venue of the recently concluded 72nd Indian Pharmaceutical Congress held from January 20-22, 2023.
During the round table series of biopharma digital transformation policy deliberations, participants heard from key figures in the industry about the challenges facing regulators in digital healthcare. This has a gathering of 50 influential policymakers, global pharma experts, and other decision-makers to discuss how the Global Tech Summit is positioned to attract the attention of the industry.
Dr. Dominique Jordan, president, International Pharmaceutical Federation, highlighted the potential impact of technology in revolutionizing drug discovery. "Digital transformation in the pharmaceutical sector involves implementing various digital technologies to improve the production and provision of healthcare products and services," he said.
"Digital transformation for the pharmaceutical industry can improve drug development, patient care, reduce carbon footprint and improves supply chain transparency," Dr. Jordan added.
Dr. Atul Nasa, president of the Indian Pharma Graduates Association, said, "Artifical I and ML can help accelerate drug discovery by analyzing large amounts of data and identifying potential drug candidates quickly and efficiently."
"Regulators must find a balance between encouraging innovation and protecting public health," said Dr. H.G. Koshia, Commissioner of Food and Drug Control Administration, Government of Gujarat.
Abhijit Ghoshi, assistant drug controller, medical device, CDSCO said "Digital transformation is inevitable, and India should take the lead in developing policies that encourage innovation while protecting public health".
Dr T V Narayana, president of the Indian Pharmaceutical Association, emphasised the importance of pharma industry and academic industry collaboration, He stated that combining the financial backing of pharma companies with early-stage drug molecules from academic institutions is a key source of innovation, with many successful assets being developed and commercialised through institutional technology out-licensing.
|